Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OMN-51
- Development stage
- Preclinical
- Lead developer
- Omnix Medical
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides
01
Overview
OMN-51 is a synthetic antimicrobial peptide (AMP) developed by Omnix Medical. It is designed to target Gram-negative bacteria, particularly Pseudomonas aeruginosa, which are responsible for recurrent and persistent infections in patients with Cystic Fibrosis (CF), Non–Cystic Fibrosis Bronchiectasis (NCFB), and Chronic Obstructive Pulmonary Disease (COPD). Preclinical studies have demonstrated that OMN-51 exhibits potent bactericidal activity against susceptible, resistant, and multidrug-resistant strains of P. aeruginosa with no observed resistance or cross-resistance. The drug is currently in preclinical development[1][2][3][6].
Beyond the preview
Go deeper on OMN-51.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OMN-51.